Filing Flows › Caribou Biosciences (CRBU) › Q3 2026
Caribou Biosciences (CRBU) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Caribou Biosciences (CRBU) reported revenue of $1.6M for the third quarter 2026 (Q3 2026), -27% from a year earlier and +7% from the quarter before.
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +7% | -27% |
| Operating profit | −$27.6M | — | — |
| Net earnings | −$26.6M | — | — |
| Operating cash flow | −$22.5M | — | — |
What changed
Revenue was $1.6M in Q3 2026, down 27% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $27.6M, an operating margin of -1720.1%. Total costs fell 7% while revenue fell 27%. The quarter ended with a net loss of $26.6M, wider than the previous quarter's $24.3M loss.
Operating cash flow was −$22.5M. Non-cash charges added back $590K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items added $1.3M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$22.5M.
Questions
What was Caribou Biosciences' revenue in the third quarter 2026?
Caribou Biosciences (CRBU) reported revenue of $1.6M for the third quarter 2026 (Q3 2026), -27% from a year earlier and +7% from the quarter before.